Table 2 The reasons for treatment discontinuation in the first-line and second-line therapy.

From: Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma

Factor

First-line therapy (n = 307) (%)

Second-line therapy (n = 131) (%)

Progressive disease

165 (54.0)

68 (51.8)

Adverse events

113 (36.7)

42 (32.1)

Fatigue

32 (10.4)

10 (7.6)

Appetite loss

22 (7.2)

10 (7.6)

Proteinuria

15 (4.9)

4 (3.1)

Liver disorder

13 (4.2)

6 (4.6)

Diarrhea

9 (2.9)

3 (2.3)

HFSR

8 (2.6)

5 (3.8)

Thrombocytopenia

5 (1.6)

1 (0.8)

Fever

4 (1.3)

2 (1.5)

Pneumonia

3 (0.9)

1 (0.8)

Skin disorders

2 (0.7)

0 (0.0)

Hepatic decompensation

16 (5.1)

12 (9.2)

Ascites

7 (2.3)

9 (6.9)

Encephalopathy

5 (1.6)

3 (2.3)

Hemorrhage

3 (0.9)

0 (0.0)

Jaundice

1 (0.3)

 

Conversion

1 (0.3)

1 (0.8)

Others

12 (3.9)

8 (6.1)

  1. HFSR hand-foot-syndrome-reaction.
Back to article page